Literature DB >> 22990267

Cardiovascular risk assessment in the development of new drugs for obesity.

William R Hiatt1, Allison B Goldfine, Sanjay Kaul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22990267     DOI： 10.1001/jama.2012.9931

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

Review 1.  Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.

Authors:  Faiez Zannad; Wendy Gattis Stough; Raymond J Lipicky; Juan Tamargo; George L Bakris; Jeffrey S Borer; Maria de Los Angeles Alonso García; Samy Hadjadj; Wolfgang Koenig; Stuart Kupfer; Peter A McCullough; Ofri Mosenzon; Stuart Pocock; André J Scheen; Harald Sourij; Bart Van der Schueren; Christina Stahre; William B White; Gonzalo Calvo
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2016-04-03

2.  Blood pressure status during consultation: a primary care study.

Authors:  Yousef Abdullah Al Turki
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-10-17

Review 3.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

4.  The small molecule indirubin-3'-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.

Authors:  O M Choi; Y-H Cho; S Choi; S-H Lee; S H Seo; H-Y Kim; G Han; D S Min; T Park; K Y Choi
Journal:  Int J Obes (Lond)       Date:  2013-11-15       Impact factor: 5.095
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.